Status: Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score \>= 10).
Participants needed: 25
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Feb 5, 2026Locations: 1
Eligibility criteria
Voluntarily sign a written informed consent form (ICF). [+10]
lymph node metastasis; [+18]